BioCentury
ARTICLE | Clinical News

Intercell falls on Staph vaccine setback

April 12, 2011 12:28 AM UTC

Intercell AG (VSE:ICLL; OTCQX:INRLY) fell EUR 2.32 (28%) to EUR 5.88 on Monday after an independent DMC recommended suspending enrollment in a Phase II/III trial of V710 to prevent Staphylococcus aureus infections following elective cardiothoracic surgery, pending further analyses of the vaccine's benefit-risk profile. The recommendation followed a pre-specified interim analysis, which included about 7,700 patients. ...